NGeneBio Finalizes 80% Dilutive Rights Offering, Prospectus Effective; Financial Distress and Delisting Risk Intensify
Following the registration statement becoming effective on July 17, 2026, NGeneBio submitted the final prospectus on July 20, 2026, to issue 7.15 million new shares representing 80.01% of outstanding shares via a rights offering with standby underwriting.
The first offering price is set at 1,074 won with a 25% discount, targeting total proceeds of approximately 7.68 billion won. The new shares are not subject to a lock-up, and the lead manager will underwrite any unsubscribed shares.
As of end-Q1 2026, the company had accumulated deficits of 75.8 billion won, a debt ratio of 224%, and a current ratio of 48.26%, indicating extreme financial weakness. Even after the capital increase, additional losses exceeding 10.7 billion won could trigger a designated management item.
The largest shareholder's stake will drop from 21.95% to 17.08%, and could further fall to 12.75% considering potential conversions of outstanding convertible bonds. The risk of being designated a management item and eventual delisting looms if market capitalization stays below 20 billion won.
[AI Summary]NGeneBio's rights offering is now finalized, inevitably causing massive 80% equity dilution. More than half of the proceeds will be used to repay high-interest debt, focusing on short-term survival rather than growth. The company's severe financial distress and delisting risk have materialized, posing significant loss risk to investors.